CAMBRIDGE, Mass., March 9 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will present
at SG Cowen Securities' 25th Annual Healthcare Conference being held in
Boston, Massachusetts, March 14-17, 2005. Michael J. Astrue, President and
Chief Executive Officer will present an overview and update of TKT's business
activities and product pipeline at 11:20 a.m. - 12:00 p.m. Eastern Time on
Wednesday, March 16, 2005. A live audio webcast of this presentation will be
available at http://www.tktx.com on TKT's Investor Information website under
the Events category. A replay will be available for approximately 30 days
after the webcast.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the company's
website at http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager of Transkaryotic Therapies, Inc., +1-617-349-0205
|
